Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Lymphoid 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

Paclitaxel 491Carboplatin 436Gemcitabine 394Docetaxel 386Cisplatin 361pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 222Dexamethasone 213Fluorouracil 212Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 161Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 140Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Factor VIII × Clear all
NCT02847637 2022-11-16

HAVEN 3

Hoffmann-La Roche

Phase 3 Completed
152 enrolled 46 charts 1 FDA
Classical hematology

Hemophilia A

NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡